Ua hoʻolaha ʻo AbbVie, kahi hui biopharmaceutical honua noiʻi, ua ʻae ʻo Health Canada i ka SKYRIZI® (risankizumab), no ka mālama ʻana i nā poʻe maʻi me nā maʻi psoriatic ikaika. Ma PsA, hiki ke hoʻohana wale ʻia ʻo SKYRIZI a i hui pū ʻia me kahi lāʻau antirheumatic hoʻololi i ka maʻi non-biologic (cDMARD) (e laʻa, methotrexate).
"Loaʻa iā SKYRIZI ka leka hoʻomaopopo no ka mālama ʻana i ka maʻi psoriatic ikaika e hāʻawi i ka manaolana hou i nā maʻi. Hōʻike nā hopena mai ka papahana hoʻokolohua lapaʻau Phase 3 i ka hoʻomaikaʻi ʻana i nā hōʻailona a me nā hōʻailona e pili ana i kēia maʻi, "wahi a Kauka Kim Alexander Papp, MD, PhD, FRCPC, FAAD, Probity Medical Research.
"Ma AbbVie, hoʻoikaika mākou e hoʻololi i ke kūlana o ka mālama ʻana i ka poʻe immunocompromised, a hauʻoli mākou i ka ʻae ʻana o Health Canada iā SKYRIZI no ka mālama ʻana i nā poʻe mākua me ka maʻi psoriatic ikaika," wahi a Tracey Ramsay, Hope Pelekikena a Luna Nui, AbbVie Canada.
ʻO kēia ka lua o ka hōʻailona no SKYRIZI ma Kanada. I ʻApelila 2019, ua ʻae ʻo Health Canada iā SKYRIZI no ka mālama ʻana i nā poʻe maʻi maʻi me ka psoriasis plaque haʻahaʻa a koʻikoʻi ka poʻe i koho no ka systemic therapy a i ʻole phototherapy.
He aha e lawe ʻia mai kēia ʻatikala:
- “At AbbVie, we strive to transform the standard of care for immunocompromised people, and we are excited with Health Canada’s approval of SKYRIZI for the treatment of adults with active psoriatic arthritis,”.
- In April 2019, Health Canada approved SKYRIZI for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
- In PsA, SKYRIZI can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.
